iPSC/HES Technology

Pluripotent Stem Cells 

Pluripotent stem cell therapies such as pluripotent stem cells (iPSC) or human embryonic stem cell (ESC) have the potential to make most of the different cells in the body in a laboratory dish and thus have great potential for the development of new cellular therapies for many diseases. Although many advances in the development of pluripotent stem cell therapies have been made. There is a need to improve the safety, scalability and feasability of this technology before the development of specific cell therapies.

The Cellular Development Team in the CPML is developing methodologies for the large-scale xeno-free culture of these cells and the translation of this technology into clinical cellular therapy protocols. If you have a iPSC or HES project ready for translation to the clinic, please contact us for more information on how we can assist you in preparation for your clinical trial.

Pluripotent Stem Cell Testing

We have two panels of tests available as a basic/preliminary or comprehensive analysis of human induced pluripotent stem cells (iPSC) and human embryonic stem cells (ESC). The basic panel includes standard sterility and mycoplasma screening, expression analysis of standard human iPSC/ESC cell surface markers by flow cytometry, karyotype, expression analysis panel of 95 genes involved in pluripiotency and differentiation. The comprehensive analysis includes immunofluorescence analysis, germ layer differentiation analysis (teratoma formation, embryoid body differentiation), tissue targeted differentiation into specific lineages (endothelial, cardiac, neural, endoderm, and/or hematopoietic differentiation), expression analysis (mRNA-seq, mi-RNA-seq), high resolution molecular karyotype (copy number variation) and epigenetic analysis (genomic DNA methylation analysis).

Contact us for more information on iPSC characterization and complete the sample submission form.

Selected References

1.  Jiang X, Gwye Y, Lutzko C, Lawlor ER.  Isolation and characterization of neural crest stem cells derivsed from in vitro-differentiated human embryonic stem cells.  Stem Cells and Development 18:259-270, 2009

2.  Melchoir K, Weib J, Zaehres H, Yong-Mi K, Lutzko C, Roosta N, Hescheler J, Muschen M.  The WNT receptor FZD7 contributes to self-renewal of signaling of human embryonic stem cells.  Journal of Biological Chemistry 389:897-903, 2008

3.  Rodriguez RT, Velkey JM, Lutzko C, Seerke R, Kohn DB, O'Shea KS, Firpo MT.  Manipulation of OCT4 levels in human embryonic stem cells results in induction of differential cell types.  Journal of Experimental Biology & Medicine 232:1368-80, 2007

4.  Jang J, Shaw K, Yu X, Petersen D, Pepper K, Lutzko C, Kohn DB.  Specific and stable gene transfer to human embryonic stem cells using pseudotyped lentiviral vectors.  Stem Cells and Development 15(1):109-17, 2006